

Beyond chemoradiation therapy: Harnessing Immunotherapy to Conquer LA-NSCLC and SCLC-LS



James Yang

Organization National Taiwan University Cancer Center
Current Position Superintendent

Educational background

1996-2000 Ph.D., College of Medicine, National Taiwan University
1979-1986 M.D., Medical College, National Taiwan University

Professional experience

2021-Present Director, Cancer Research Center, College of Medicine, National Taiwan University
2020-Present Staff Physician, Department of Medical Oncology, National Taiwan University Cancer Center and Department of Oncology, National Taiwan University Hospital
2009-Present Professor, Graduate Institute of Oncology, Graduate Institute of Clinical Pharmacy, Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University

The management of locally advanced non-small cell lung cancer (LA-NSCLC) and limited-stage small cell lung cancer (SCLC-LS) has historically relied on definitive chemoradiation, with modest survival benefits and a persistent risk of recurrence. Recent breakthroughs in immunotherapy, particularly as post-chemoradiation consolidation, have redefined the therapeutic landscape for these challenging malignancies. This session, entitled “Beyond Chemoradiation Therapy: Harnessing Immunotherapy to Conquer LA-NSCLC and SCLC-LS,” will provide a comprehensive overview of the latest clinical advances, practical approaches, and evolving future directions.

The first focus will be the pivotal PACIFIC trial, which established durvalumab consolidation as standard of care for unresectable LA-NSCLC following chemoradiation. Five-year follow-up data from PACIFIC have definitively confirmed sustained improvements in both progression-free and overall survival, with 42.9% of patients alive at five years in the durvalumab arm versus 33.4% in the placebo arm, and a favorable long-term safety profile. These results underscore the durable benefit and transformative impact of immunotherapy in this setting. For SCLC-LS, the recently published ADRIATIC trial marks a groundbreaking advance, standing as the only successful trial demonstrating the efficacy of immunotherapy consolidation following chemoradiation. The session will also discuss ADRIATIC’s robust clinical outcomes and its significance in shifting the treatment paradigm for SCLC-LS.